KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors

BACKGROUND: Adenoid cystic carcinoma (ACC) is a rare cancer with an aggressive phenotype and the high incidence of recurrence and distant metastasis severely affects the overall survival of ACC patients. Understanding the molecular mechanisms that drives ACC could improve the treatment and outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Helei, Jia, Dongmei, Yan, Weihua, Zhang, Xiaoping, Wang, Chunbao, Li, Yujun, Chen, Hua, Huang, Weiqing, Li, Zhuokun, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797755/
https://www.ncbi.nlm.nih.gov/pubmed/35117834
http://dx.doi.org/10.21037/tcr-20-637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797755/
https://www.ncbi.nlm.nih.gov/pubmed/35117834
http://dx.doi.org/10.21037/tcr-20-637

Ejemplares similares